Breast Cancer
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20, 2022
An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Steven J. Chmura, MD, PhD, compares addition of metastases-directed therapy vs SOC alone for oligometastatic breast cancer
July 12, 2022
Steven J. Chmura, MD, PhD, discussed recent findings from the phase 2R/3 NRG-BR002 trial in patients with newly diagnosed oligometastatic breast cancer.
Study reveals drivers of breast cancer awareness and mammography compliance
June 28, 2022
Gynecologists and physicians, in concert with mothers, are key not only to a woman’s early awareness of both breast cancer and mammography but to awareness of breast cancer risk factors as well.
COVID-19 delays cancer screenings, deaths expected to rise in next 10 years
March 22, 2022
Cancer programs seek to remove barriers to screenings.
Addressing inequities in cancer care starts with awareness
March 21, 2022
Alexander B. Olawaiye, MD, discusses how social and biological determinants can affect care outcomes across cancer subtypes and what steps community and academic oncologists can take to ensure these disparities are recognized.
A customized cure for ERBB2-positive metastatic breast cancer
February 24, 2022
Novel therapies could potentially expand the population of patients with ERBB2-positive metastatic breast cancer who experience long-lasting disease response, according to a review in JAMA Oncology.
Breast cancer diagnosis during and before pandemic
February 23, 2022
A quality improvement study in JAMA Network Open has found that a significantly lower percentage of patients with breast cancer presented with stage I disease before the COVID-19 pandemic, in 2019, compared to after the start of the pandemic, in 2020.
Trastuzumab deruxtecan significantly improves PFS, OS in HER2-low metastatic breast cancer
February 22, 2022
Trastuzumab deruxtecan resulted in a statistically significant improvement in progression-free survival and overall survival compared with physician’s choice of chemotherapy in patients with HER2-low unresectable and/or metastatic breast cancer, irrespective of hormone receptor status, meeting the primary and secondary end points of the phase 3 DESTINY-Breast 04 trial.
Hologic announces Super Bowl advertising campaign with Mary J. Blige
February 02, 2022
The campaign emphasizes the importance of annual cancer screenings with the Queen of Hip-Hop Soul
Survival benefit for chemotherapy addition demonstrated for premenopausal patients with HR+/HER2– breast cancer
December 24, 2021
Investigators of the SWOG S1007 RxPONDER trial found a statistically significant improvement in invasive disease-free survival and distant relapse-free survival in premenopausal women who received adjuvant chemotherapy.